"In my opinion, given the low float, it should be obvious that positive Phase 2b results will be highly accretive to the stock price. "
"Accretive is the process of accretion, which is growth or increase by gradual addition, in finance and general nomenclature. An acquisition is considered accretive if it adds to the item's value or corporation's earnings per share." Accretive Definition | Investopedia
Your conclusion seems counter to the original post.
The great thing is NTRP is running a blinded placebo controlled trial. Imagine if they were targeting "cellular homeostasis" for example to treat Alzheimer's, and doing it in an unblinded trial.
"Homeostasis in a general sense refers to stability or balance in a system.
Oddly enough the reason that clinical trials like NTRP's should be blinded has to do with an Australian scam that was predicated on "balance".
Running an unblinded non-placebo controlled trial is an invitation for investigator bias and misleading "practice effect". Thank goodness NTRP is running a proper trial that is actually a Phase 2b not a phase 2a who's primary endpoint is dose optimization that they hope will "fail quickly".
Market Data 
Markets 
AI
